Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD

9 May 2024

Abstract excerpt

Vancomycin and metronidazole are commonly used treatments for Clostridioides difficile infection (CDI).However, these antibiotics have been associated with high levels of relapse in patients.Fidaxomicin is a new treatment for CDI that is described as a narrow spectrum antibiotic that is minimally active on the commensal bacteria of the gut microbiome.The aim of this study was to compare the effect of fidaxomicin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Identification and Susceptibility Testing
Share to Clostridium difficile and Clostridium perfringens research
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38722061
DOI: 10.1080/19490976.2024.2342583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CDPMID 38722061Read ↗

Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficileSemantic proximity Read ↗

Probiotics: insights and new opportunities for Clostridioides difficile interventionSemantic proximity Read ↗

Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Semantic proximity Read ↗

<i>In Vitro</i> Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of <i>Staphylococcus</i> spp. and <i>Enterococcus</i> sppSemantic proximity Read ↗

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to FidaxomicinSemantic proximity Read ↗

Antimicrobial Susceptibility and Molecular Characterization Using Whole-Genome Sequencing of Clostridioides difficile Collected in 82 Hospitals in Japan between 2014 and 2016Semantic proximity Read ↗

High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile in vitroSemantic proximity Read ↗

Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.Semantic proximity Read ↗

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficileSemantic proximity Read ↗

<i>In vivo</i> efficacy of fidaxomicin against <i>rpoB</i> mutant <i>Clostridioides difficile</i> infectionSemantic proximity Read ↗

Clinical and pharmacoeconomic evaluation of fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infectionSemantic proximity Read ↗

Basis of narrow-spectrum activity of fidaxomicin on gut pathogen <i>Clostridioides difficile</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.